Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1886 1
1902 1
1942 2
1943 1
1945 2
1946 9
1947 17
1948 21
1949 19
1950 24
1951 13
1952 19
1953 19
1954 17
1955 17
1956 24
1957 28
1958 27
1959 28
1960 11
1961 11
1962 32
1963 44
1964 40
1965 42
1966 44
1967 47
1968 30
1969 38
1970 30
1971 38
1972 26
1973 21
1974 31
1975 30
1976 47
1977 34
1978 40
1979 20
1980 32
1981 31
1982 20
1983 23
1984 18
1985 33
1986 35
1987 34
1988 30
1989 36
1990 40
1991 48
1992 38
1993 63
1994 48
1995 49
1996 60
1997 44
1998 50
1999 60
2000 42
2001 74
2002 51
2003 68
2004 78
2005 78
2006 66
2007 76
2008 96
2009 81
2010 97
2011 92
2012 106
2013 109
2014 115
2015 112
2016 132
2017 97
2018 103
2019 111
2020 113
2021 130
2022 99
2023 108
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

3,750 results

Results by year

Filters applied: . Clear all
Page 1
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP. Glaviano A, et al. Among authors: brown jr. Mol Cancer. 2023 Aug 18;22(1):138. doi: 10.1186/s12943-023-01827-6. Mol Cancer. 2023. PMID: 37596643 Free PMC article. Review.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M. Brown JR, et al. N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13. N Engl J Med. 2023. PMID: 36511784 Clinical Trial.
PI3K inhibitors are finally coming of age.
Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. Vanhaesebroeck B, et al. Among authors: brown jr. Nat Rev Drug Discov. 2021 Oct;20(10):741-769. doi: 10.1038/s41573-021-00209-1. Epub 2021 Jun 14. Nat Rev Drug Discov. 2021. PMID: 34127844 Free PMC article. Review.
Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE, Brown JR. Ahn IE, et al. Among authors: brown jr. Front Immunol. 2021 Jun 23;12:687458. doi: 10.3389/fimmu.2021.687458. eCollection 2021. Front Immunol. 2021. PMID: 34248972 Free PMC article. Review.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Mato AR, et al. Among authors: brown jr. Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5. Lancet. 2021. PMID: 33676628 Clinical Trial.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trněný M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P. Tam CS, et al. Among authors: brown jr. Lancet Oncol. 2022 Aug;23(8):1031-1043. doi: 10.1016/S1470-2045(22)00293-5. Epub 2022 Jul 7. Lancet Oncol. 2022. PMID: 35810754 Clinical Trial.
PICRUSt2 for prediction of metagenome functions.
Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, Huttenhower C, Langille MGI. Douglas GM, et al. Among authors: brown jr. Nat Biotechnol. 2020 Jun;38(6):685-688. doi: 10.1038/s41587-020-0548-6. Nat Biotechnol. 2020. PMID: 32483366 Free PMC article. No abstract available.
AAV gene therapy for Tay-Sachs disease.
Flotte TR, Cataltepe O, Puri A, Batista AR, Moser R, McKenna-Yasek D, Douthwright C, Gernoux G, Blackwood M, Mueller C, Tai PWL, Jiang X, Bateman S, Spanakis SG, Parzych J, Keeler AM, Abayazeed A, Rohatgi S, Gibson L, Finberg R, Barton BA, Vardar Z, Shazeeb MS, Gounis M, Tifft CJ, Eichler FS, Brown RH Jr, Martin DR, Gray-Edwards HL, Sena-Esteves M. Flotte TR, et al. Among authors: brown rh jr. Nat Med. 2022 Feb;28(2):251-259. doi: 10.1038/s41591-021-01664-4. Epub 2022 Feb 10. Nat Med. 2022. PMID: 35145305 Free PMC article.
Molecular map of chronic lymphocytic leukemia and its impact on outcome.
Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, Tausch E, Delgado J, Barbera-Mourelle A, Taylor-Weiner A, Bousquets-Muñoz P, Diaz-Navarro A, Dunford A, Anand S, Kretzmer H, Gutierrez-Abril J, López-Tamargo S, Fernandes SM, Sun C, Sivina M, Rassenti LZ, Schneider C, Li S, Parida L, Meissner A, Aguet F, Burger JA, Wiestner A, Kipps TJ, Brown JR, Hallek M, Stewart C, Neuberg DS, Martín-Subero JI, Puente XS, Stilgenbauer S, Wu CJ, Campo E, Getz G. Knisbacher BA, et al. Among authors: brown jr. Nat Genet. 2022 Nov;54(11):1664-1674. doi: 10.1038/s41588-022-01140-w. Epub 2022 Aug 4. Nat Genet. 2022. PMID: 35927489 Free PMC article.
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Byrd JC, et al. Among authors: brown jr. Blood. 2021 Jun 17;137(24):3327-3338. doi: 10.1182/blood.2020009617. Blood. 2021. PMID: 33786588 Free PMC article. Clinical Trial.
3,750 results